Chemicals

2nd Quarter 2017

Sales in the Chemicals segment considerably exceeded the level of the previous second quarter. This was largely the result of significantly higher prices, especially in the Monomers division. Currency effects had a positive influence on sales, whereas volumes declined slightly. Income from operations (EBIT) before special items improved considerably compared with the second quarter of 2016, primarily through higher margins in the Monomers and Petrochemicals divisions. The negative impact on earnings in the second quarter of 2017 caused by the North Harbor accident at the Ludwigshafen site was compensated by insurance payments. Fixed costs were slightly reduced overall.

Factors influencing sales, Chemicals
2nd Quarter 2017

Factors influencing sales, Chemicals – 2nd Quarter 2017 (bar chart)

Petrochemicals

Sales in the Petrochemicals division increased considerably compared with the previous second quarter. Higher prices for raw materials as well as continuing high demand on the market led to a significant spike in sales prices, especially for steam cracker products in Europe. Sales volumes declined slightly overall, primarily as a consequence of the still-limited production of oxo alcohols and plasticizers in Ludwigshafen. Improved margins, especially for steam cracker products, ethylene oxide, glycols and acrylic monomers, led to a considerable increase in EBIT before special items. Fixed costs declined thanks to insurance payments in connection with the accident at the North Harbor.

Monomers

Compared with the second quarter of 2016, sales in the Monomers division grew considerably, mostly as a result of price increases in the isocyanates business. Sales volumes rose slightly, predominantly through higher volumes of MDI, and currency effects provided a slight tailwind. The considerable increase in EBIT before special items arose primarily through the higher levels of prices and volumes. Earnings were also positively influenced by the restructuring of our caprolactam production in Europe. Fixed costs declined compared with the same quarter of the previous year.

Intermediates

The Intermediates division also considerably increased its sales, primarily as a result of price increases in all regions and product lines. Sales volumes remained stable. We achieved higher volumes of amines in addition to polyalcohols and acids, while sales volumes decreased of butanediol and derivatives as well as acetylene and carbonyl derivatives due to more extensive plant maintenance turnarounds. The divestiture of the Evans City, Pennsylvania, site in the first quarter of 2017 slightly dampened sales growth. The turnarounds and the startup of new plants in all regions resulted in higher fixed costs, considerably reducing EBIT before special items.

Segment data Chemicals1 (million €)

 

 

2nd Quarter

1st Half

 

 

2017

2016

Change %

2017

2016

Change %

1

On January 1, 2017, the Monomers and Dispersions & Pigments divisions’ activities for the electronics industry were merged into the global Electronic Materials business unit and allocated to the Dispersions & Pigments division. For better comparability, the affected figures for 2016 have been adjusted accordingly.

2

Amortization of intangible assets and depreciation of property, plant and equipment (including impairments and write-ups)

3

Additions to intangible assets and property, plant and equipment

Sales to third parties

 

4,045

3,236

25

8,150

6,255

30

Thereof Petrochemicals

 

1,580

1,322

20

3,234

2,518

28

Monomers

 

1,708

1,234

38

3,407

2,411

41

Intermediates

 

757

680

11

1,509

1,326

14

Income from operations before depreciation and amortization (EBITDA)

 

1,385

717

93

2,624

1,436

83

Amortization and depreciation2

 

266

259

3

531

518

3

Income from operations (EBIT)

 

1,119

458

144

2,093

918

128

Special items

 

(1)

.

15

3

400

EBIT before special items

 

1,120

458

145

2,078

915

127

Assets (June 30)

 

12,892

12,483

3

12,892

12,483

3

Investments including acquisitions3

 

230

316

(27)

413

592

(30)

Research and development expenses

 

31

36

(14)

60

72

(17)